Alterity Therapeutics Stock (NASDAQ:ATHE)


OwnershipChart

Previous Close

$1.12

52W Range

$1.01 - $5.41

50D Avg

$1.23

200D Avg

$1.67

Market Cap

$9.73M

Avg Vol (3M)

$12.06K

Beta

0.68

Div Yield

-

ATHE Company Profile


Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

AU

Employees

10

IPO Date

Sep 29, 2003

Website

ATHE Performance


Latest Earnings Call Transcripts


Q2 21Feb 25, 21 | 10:42 PM

Peer Comparison


TickerCompany
PMVPPMV Pharmaceuticals, Inc.
MNPRMonopar Therapeutics Inc.
ADILAdial Pharmaceuticals, Inc.
RVPHReviva Pharmaceuticals Holdings, Inc.
ADTXAditxt, Inc.
ARTLArtelo Biosciences, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
SRZNSurrozen, Inc.
RNAZTransCode Therapeutics, Inc.
VCNXVaccinex, Inc.
ANTXAN2 Therapeutics, Inc.
HCWBHCW Biologics Inc.
ANEBAnebulo Pharmaceuticals, Inc.
TARAProtara Therapeutics, Inc.
ATXIAvenue Therapeutics, Inc.
ABIOARCA biopharma, Inc.
ELYMEliem Therapeutics, Inc.